Advanced Technologies - National Center for Image Guided Therapy (AT-NCIGT)

先进技术 - 国家影像引导治疗中心 (AT-NCIGT)

• 批准号: 10540773
• 负责人: CLARE M TEMPANY
• 金额: $ 139.14万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-06 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10540773
• 关键词: 3-Dimensional; Acceleration; Acute; Algorithms; Architecture; Atlas of Cancer Mortality in the United States; Augmented Reality; Biomedical Research; Biopsy Specimen; Blood; Brain; Brain Neoplasms; Cells; Characteristics; Communities; Compensation; Complex; Computer Vision Systems; Computer software; Conventional Surgery; Data; Dedications; Development; Devices; Diffusion; Discipline; Disease; Early Diagnosis; Effectiveness; Evolution; Foundations; Goals; Healthcare; Heterogeneity; Histopathology; Image; Imaging Device; Imaging Techniques; Immunotherapy; Implant; Individual; Information Retrieval; Infrastructure; Intervention; Interventional radiology; Knowledge; Lesion; Longitudinal Studies; Lung; Magnetic Resonance; Magnetic Resonance Imaging; Malignant neoplasm of prostate; Maps; Medical; Medicine; Metabolic; Metabolic Marker; Metabolism; Metadata; Methods; Microscopic; Mission; Modeling; Molecular; Morphology; Nanotechnology; Navigation System; Needles; Neoplasm Metastasis; Operating Rooms; Operative Surgical Procedures; Patient Care; Patient-Focused Outcomes; Pattern; Physiologic pulse; Procedures; Prostate; Radiation Oncology; Recurrence; Research; Resistance; Retrieval; Risk Assessment; Sampling; Services; Signal Transduction; Source; Specimen; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Speed; T2 weighted imaging; Technology; Testing; Time; Tissue Sample; Tissue imaging; Tissues; Visualization; big-data science; biomedical resource; brain surgery; cancer care; cancer heterogeneity; cancer imaging; cancer therapy; data curation; data integration; deep learning; design; digital; image guided; image guided therapy; image registration; imaging facilities; imaging modality; improved; in vivo; in vivo monitoring; innovation; ion mobility; learning strategy; machine learning algorithm; mass spectrometer; mass spectrometric imaging; microdevice; neoplastic; new technology; novel; novel strategies; personalized cancer therapy; personalized medicine; precision medicine; prostate biopsy; protocol development; response; surgery outcome; technology platform; technology research and development; technology validation; tissue oxygenation; tool; trait; tumor; tumor heterogeneity; tumor hypoxia; ultra high resolution

ABSTRACT: The intersection of healthcare and biomedical research is at an inflection point with the convergence of the digital revolution, advances in imaging, nanotechnology, big data science, and precision or personalized medicine. There is a wealth of meaningful, but complex information that could be extracted from imaging data but is not optimally utilized for patient care. Cancer care exemplifies the current challenges which include early detection, accurate distinction of pre- neoplastic and neoplastic lesions, prediction of tumor aggressiveness, determining infiltrative tumor margins during surgical treatment, tracking tumor evolution/ metastasis pattern, recurrence, and potential acquired resistance to treatments over time. Major strides have been made in the personalization of cancer therapies such as immunotherapy, but the availability of specific, relevant, and timely medical data and information is of critical importance to realizing the full potential of precision medicine. Nowhere is this more acutely evident than during interventions in the operating and procedure rooms. Novel methods of image guidance, data integration, information extraction, and knowledge transfer are needed to enable clinicians to fully leverage the information available, especially before, during and after invasive procedures. We are excited to re-submit a proposal for a new P41 biomedical resource center (BTRC) called Advanced Technologies for NCIGT(AT-NCIGT) with 3 TRDs, 10 new collaborative and 10 new service projects, all of which aim to investigate develop and disseminate new technologies for image guided therapy (IGT). The 3 components are Imaging Cancer Heterogeneity for IGT, Deep Learning for IGT and Intraoperative devices for IGT. These new technologies alone and in combinations will allow for greater understanding of disease state, treatment guidance, integration/navigation and in-vivo monitoring of tissue responses and improve the precision of invasive procedures. Thus the overall goal of this proposal is to investigate, develop and disseminate novel technologies for extracting new tissue characteristics (technology research and development core TRD 1: Imaging cancer heterogeneity; analyze them and make them available through state-of-the-art algorithmic and data curation approaches (Deep Learning TRD 2); and enable precise tissue sampling surgical navigation and in-vivo tissue response through the results of novel Intraoperative devices (Intraoperative devices for IGT: TRD 3). In order to effectively disseminate all this new knowledge we have 10 new collaborative and 10 new service projects and will share these novel tools through our established mechanisms, from current BTRC- National Center for Image Guided Therapy (NCIGT), which continues to be dedicated to the innovating for IGT into interventional radiology, surgery, radiation oncology, and procedure-based medicine.

摘要：医疗保健和生物医学研究的交叉点正处于一个转折点， 数字革命的融合，成像，纳米技术，大数据科学的进步， 精准或个性化医疗。有大量有意义但复杂的信息， 从成像数据中提取，但不能最佳地用于患者护理。癌症护理证实了 目前的挑战包括早期检测，肿瘤前和肿瘤的准确区分， 病变，预测肿瘤侵袭性，在手术期间确定浸润性肿瘤边缘 治疗，跟踪肿瘤演变/转移模式，复发和潜在的获得性耐药性， 治疗随着时间的推移。在癌症治疗的个性化方面取得了重大进展， 免疫治疗，但具体的，相关的，及时的医疗数据和信息的可用性是 这对实现精准医疗的全部潜力至关重要。没有什么比这更尖锐的了 比在手术室和手术室进行干预时更明显。图像的新方法 需要指导、数据集成、信息提取和知识转移， 临床医生充分利用现有的信息，特别是在侵入性手术之前、期间和之后， 程序.我们很高兴重新提交一个新的P41生物医学资源中心（BTRC）的建议 称为先进技术NCIGT（AT-NCIGT）与3 TRD，10个新的合作和10个新的 服务项目，所有这些项目的目的都是调查、开发和传播新的图像技术。 指导治疗（IGT）。3个组成部分是IGT的癌症异质性成像，深度学习 用于IGT和用于IGT的术中器械。这些新技术单独和组合将 允许更好地了解疾病状态、治疗指导、整合/导航和体内 监测组织反应并提高侵入性手术的精确度。 因此，本提案的总体目标是研究、开发和传播新技术， 提取新的组织特征（技术研发核心TRD 1：癌症成像 异构性;分析它们并通过最先进算法和数据提供它们 策展方法（深度学习TRD 2）;并实现精确的组织采样手术导航和 通过新型术中器械的结果观察体内组织反应（ IGT：TRD 3）。为了有效地传播所有这些新知识，我们有10个新的合作和 10个新的服务项目，并将通过我们建立的机制分享这些新的工具， 目前的BTRC-国家图像引导治疗中心（NCIGT），继续致力于 IGT向介入放射学、外科学、放射肿瘤学和基于程序的 药